Renaissance Technologies (RenTech)'s CNTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 508,329 shares of Context Therapeutics Inc. (CNTX) worth $747,244, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CNTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 272,435 shares. Largest reduction occurred in Q1 2023, reducing 86,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Context Therapeutics (CNTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Context Therapeutics (CNTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +188,202 | Add 58.79% | 508,329 | $1.47 |
| Q3 2025 | -43,803 | Reduce 12.04% | 320,127 | $0.97 |
| Q2 2025 | -61,570 | Reduce 14.47% | 363,930 | $0.66 |
| Q1 2025 | +87,065 | Add 25.73% | 425,500 | $0.61 |
| Q4 2024 | +272,435 | Add 412.78% | 338,435 | $1.05 |
| Q3 2024 | +800 | Add 1.23% | 66,000 | $1.96 |
| Q2 2024 | +25,300 | Add 63.41% | 65,200 | $2.00 |
| Q1 2024 | +7,700 | Add 23.91% | 39,900 | $1.38 |
| Q4 2023 | +2,100 | Add 6.98% | 32,200 | $1.12 |
| Q3 2023 | +1,800 | Add 6.36% | 30,100 | $1.50 |
| Q2 2023 | +9,100 | Add 47.40% | 28,300 | $0.00 |
| Q1 2023 | -86,100 | Reduce 81.77% | 19,200 | $0.00 |
| Q4 2022 | -25,288 | Reduce 19.36% | 105,300 | $0.00 |
| Q3 2022 | +130,588 | New Buy | 130,588 | $1.11 |
| Q2 2022 | -20,309 | Sold Out | 0 | $0.00 |
| Q1 2022 | -44,309 | Reduce 68.57% | 20,309 | $2.17 |
| Q4 2021 | +64,618 | New Buy | 64,618 | $2.66 |
Renaissance Technologies (RenTech)'s Context Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Context Therapeutics Inc. (CNTX) in Q4 2021, acquiring 64,618 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Context Therapeutics Inc. (CNTX) for 17 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Context Therapeutics Inc. (CNTX) was in Q4 2024, adding 338,435 shares worth $355,357.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 508,329 shares of Context Therapeutics Inc. (CNTX), valued at approximately $747,244.
As of the Q4 2025 filing, Context Therapeutics Inc. (CNTX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Context Therapeutics Inc. (CNTX) was 508,329 shares, as reported at the end of Q4 2025.